

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

HARDERN et al

Serial No. **09/508,195**

Filed: **March 8, 2000**

For: **NOVEL COMPOUNDS**



Atty. Ref.: **3764-2**

Group: **1624**

Examiner: **Ford, J.**

TECH CENTER 1600/2900

DEC 28 2001

RECEIVED

Honorable Commissioner of
Patents and Trademarks
Washington, DC 20231

DECLARATION

Sir:

We, Anthony H. Ingall and Brian Springthorpe, do hereby declare and state as follows:

1. Anthony H. Ingall:

My current job title with AstraZeneca UK Limited is "Associate Principal Scientist". I have been employed by AstraZeneca UK Limited and its predecessor companies for 26 years and, during all of that time, I have worked in the Department of Medicinal Chemistry primarily as a laboratory worker and supervisor of laboratory workers; but I also have certain administrative duties. At the time of the work in question, I directed a team of 5 people. I received my undergraduate degree from Imperial College, University of London, England in 1970 and my PhD also from Imperial College in 1973. My technical expertise is in the field of medicinal chemistry and synthetic organic chemistry.

2. Brian Springthorpe:

My position within AstraZeneca UK Limited is "Team Leader Medicinal Chemistry, AZ Charnwood". I have been employed with AstraZeneca UK Limited and

its predecessor companies for 30 years. I currently have responsibility for 6 people. I obtained a B.Sc. Chemistry (Hons 1st class) in 1976 from De Montfort University, and an M.Sc. in 1978 from the University of East Anglia. I have in excess of 20 years experience in the fields of medicinal chemistry and synthetic organic chemistry.


3. Attached are copies of laboratory note book pages of research chemists working under our direct supervision and control on this project. For the nine compounds exemplified in the application, five of the compounds were synthesized prior to September 21, 1998. The details are as follows:

Example Number	AR-C Number	Chemist Name	Lab Notebook Number	Page Numbers
1	130284	Andrew Bailey	2307	159-160
2	126583	Gemma Cansell	2345	25-26
3	126532	Simon Gulle	2335	47-48
4	130234	Barry Teobald	2295	178-183
5	130237	Barrie Martin	2274	157-156

4. In each case, attached is a copy of the cover showing the book number together with the relevant pages from the book. In several cases, the chemist lists the experiments carried out in a particular book at the front of the book. Where this is the case, such pages are attached to demonstrate that this represents the standard notebook. Where this was not available, the next page in the book is attached as evidence of routine standard use of the book.

5. The practice involves dating the top of the page at the start of the experimental with the date an experiment is started, demonstrating conception of the idea. Upon completing the experiment, the chemist signs and dates the end of the experimental write-up. The book is then countersigned and dated (note that for book 2274 page 158, there is a typographical error on the sign-off date - signed as "97" not "98").

We each declare that all statements herein of our own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that wilful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such wilful false statements may jeopardize the validity of the application or any patent issuing thereon.



Anthony H. Ingall

19 November 2001

Date



Brian Springthorpe

19 November 2001

Date

Attachments

2307


Andrew Bailey

2242 \leftarrow 2307 \rightarrow 2407
previous next
book book


13/8/78 Prepⁿ of [1R-(1a,2a,3b,5b (1R*, 2S*))]-3-[7-
 A. Bailey ((2-(4-fluorophenyl)cyclopropyl)amino)-5-(3,3,3
 trifluoropropylthio)-3H-1,2,3-triazolo[4,5-d]
 pyrimidin-3-yl)-5-hydroxymethyl-cyclopentane-1,2-d

AB

AB



AB



AB

Method

AB

The S.M (1.4g) was dissolved in a mixture of trifluoroacetic acid (10ml) and water (2ml) and the solⁿ left to stand for 50 mins at R.T

AB

TLC EtOAc/isohex (1/1)

SM.	○
R.M	○ ○

AB

work up

RM diluted with EtOAc and washed with xs aq bicarb, organic layer dried, filtered and vaccd down

AD

purification Flash column, 5 → 6% MeOH in CHCl_3

AB

Yield = 440 mg 'pure' + 250 mg 'less pure'

AB

AN^o 298797 of the 440 mg of 'pure' foam

AB

HP_LC 99.4% major impurity 0.23%

AB

MS APCI (+ve), $M+H = 529$

AB

NMR δ DMSO 9.42 (d, 1H, NH), 7.27-7.22 (m, 2H, aroms), 7.14-7.08 (m, 2H, aroms), 5.01-4.95 (m, 2H, CH+OH), 4.73-4.70 (m, 2H, 2OH), 4.44-4.41 (m, 1H, CH), 3.87-3.84 (m, 1H, CH), 3.50-3.45 (m, 2H, CH₂), 3.26-3.13 (m, 3H, 3CH), 2.60-2.55 (m, 1H, CH), 2.28-2.20 (m, 2H, CH₂), 2.10-2.06 (m, 1H, CH), 1.90-1.80 (m, 1H, CH), 1.49-1.46 (m, 1H, CH), 1.33-1.30 (m, 1H, CH)
missing H under solvent peak at 2.5?

AB

MA Theory is for 0.42 moles H_2O i.e. MWt = 536
Theory C = 49.30 H = 4.67 N = 15.68 S = 5.98
found 48.91 4.38 15.62 5.92

AB

410 mg submitted as 130284XX

AB

AN^o 298852 of the less pure 250 mg

AB

MS/NMR okay, HP_LC 97.6% major imp 0.48%


AB

180 mg as 130284XX Batch 2

A. Bailen 22/9/98

COMPLETED
READ AND UNDERSTOOD BY R. Jewell 02 OCT 1998

17/8/98 Prep^{er} at
A. Bailey



AD

 $C_{27}H_{31}F_3N_6O_3S_2$ (608.7)

 $C_{24}H_{27}F_3N_6O_3S$ (568.6)

AB

Method

AB

The S.M. (0.3g) was dissolved in a mixture of trifluoroacetic acid (10ml) and water (2ml) and the R.M. was left to stand for 30 mins at R.T.

AB

TLC 4% MeOH in $CHCl_3$


SM	0
RM	000

AB


Work up RM partitioned between EtOAc and xs aq bicarb, the organic layer was dried, filtered and vaced down.

2045


21




23




25




27




29




31




33



35




37



9/27/7/98. PREPARATION OF [3aR-(3aa, 4a, 6a (12*, 25*), (6aa)]-6-(7-
~~7~~ ~~fluor~~ [[2-(3,4-DIFLUOROPHENYL)CYCLOPROPYL]AMINO]-5-(3,3,3-
 TRIFLUOROPROPYLTHIO)-3H-[1,2,3]-TRIAZOLO[4,5-d]
 PURIMIDIN-3-YL] CYCLOPENTANE 1,2-DIOL.

Me



Pu

METHOD The S.M (360mg, 0.614mmol) was dissolved in 10ml of methanol. The solution was treated with dilute aq. HCl (2ml, 3M). The EM was left to stand at RT for 2 1/2 hours.

TLC EtOAc / Isohexane (-partn)

JM.		○
AK.	○	○
EM.	○	⋯

+

N

WORK UP E.M was partitioned between EtOAc + NaHCO₃. Organic layer was separated, dried and vaccd. down.

[Signature]

[Signature]

PURIFICATION. FLASH COLUMN, BIOTAGE, EthylAcetate (3) Isohexane (1).
Removes S.M and final Product.

YIELD 229mg of white foam (68%).

MS

AN APCI(+ve) M+H = 547.3 / (-ve) = 545.2.

MS

298022

NMR

δ DMSO D_6 , 9.43 (O, 1H, NH), 7.35-7.28 (M, 2H, ARO)
7.02-7.14 (M, 1H, ARO), 5.01-4.96 (M, 2H), 4.72-4.69
(T, 2H) 4.44-4.41 (Q, 1H) 3.97-3.84 (Q, 1H) 3.50-3.44
(M, 2H) 3.25-3.12 (M, 3H), 2.58-2.56 (M, 1H), 2.28-
2.21 (M, 3H), 1.76-1.91 (M, 1H), 1.52-1.50 (M, 1H),
1.39-1.37 (M, 1H), 1H MISSING, SUSPECTED UNDER
SOLVENT.

HPLC

99.7%

COMPLETED 10/9/98
READ AND UNDERSTOOD BY g.m. Shally 18/9/98

ELEMENTAL

Theory

C=48.35% H=4.24% N=15.38% S=5.87% F=17.36%

FOUND

49.38

4.71

15.26

5.71

IR

(1% extra on hydrate)

IR

cm ⁻¹	(%T)
9603	96.03
7571	75.71
7617	76.17
8735	87.35
8714	87.14
8543	85.43
7045	70.45
7247	72.47
7635	76.35
7328	73.28
7206	72.06
7484	74.84
8416	84.16
7889	78.89
8372	83.72
8247	82.47
7617	76.17
7912	79.12
7392	73.92

120mg entered as:-
135mg
126583 x x

233










SIMON D GUILF

MEDICINAL CHEMISTRY

ASTRA CITRANWOOD


PREVIOUS BOOK 2250

NEXT BOOK 2509

Page	Preparation of	Yield	ARC #
45.		42%	-
47.		48%	AR-C 126532XX
49.		73%	AR-C 126533XX
51.		53%	AR-C 126534XX
53.		31%	AR-C 120492XX BATCH 3
55.		82%	-
57.		100%	-
59.		3%	-
61.		42% 3%	-



15/7/98

PREPARATION OF ~~1,2,3,4~~ [12-[1 α ,2 β ,3 β (12 α ,25 α),5 β]]-3-[7-[(3,4-DIFLUOROPHENYL)CYCLOPROPYL]AMINO-S-(PROPYLTHTIO)-3H-1,2,3-TRIAZOLO[4,5-d]PYRIMIDIN-3-YL]-S-[(2-HYDROXY)ETHYL]CYCLOPENTANE-1,2-DIOL



(474.383)

2335/45A



(522.675)

C₂₃H₂₈F₂N₆O₄SAMOUNTS

(474.383)	SUBSTRATE	75 mg , 0.16 mmol , 1eq
(319.26) 0.742	AMINE TARTRATE	66 mg , 0.21 mmol , 1.3eq
(129.25)	DIPET	83 μ l , 0.47 mmol , 3eq
	DCM	5 ml

EXPERIMENTAL

A mixture of the above reagents was stirred at rt for 24 hrs. The reaction mixture was absorbed on to silica and purified (Biotage 111 K₂OAc/Hex).

⇒ 2335/47A

AN 297523

LC/MS APCI + 563 (M+H)⁺ >99% pure

The protected compound was treated with TFA/H₂O (10 ml; 9:1) for 10 mins then concn in vacuo. The residue (mixture of prod + TFA ester) was treated with K₂CO₃ (100 mg) in MeOH/H₂O (10 ml; 1/1) for 1 hr.

This mixture was added to remove MeOH. The remainder was partitioned between water (20ml) and EtOH (3x20ml). The combined organic phase was dried (MgSO_4) and removed in vacuum then triturated with pentane to produce a solid

\Rightarrow 2335/48A Purified RP4AC \Rightarrow 2335/48B 40mg, 48%

AN 297547 (48A) / 297735 (48B)

WMS 98.4% MAJOR IMPURITY 1.4% APC + 523 (with T)

IR

EA FOUND C 50.64% H 5.43% N 15.87% S 5.72%

REQUIRED C 51.10% H 5.59% N 15.55% S 5.93%

FOR $\text{C}_{23}\text{H}_{28}\text{F}_2\text{N}_6\text{O}_4\text{S} \cdot \text{H}_2\text{O}$ FW 540.59.

¹H NMR
DMSO

0.79-1.00 (m, 3H), 1.20-1.75 (m, 4H), 1.96-2.30 (m, 2H),
2.58-2.70 (m, 1H), 2.80-3.20 (m, 3H), 3.43-3.58 (m,
4H), 3.73-3.80 (m, 1H), 3.90-3.96 (m, 1H), 4.50-4.61
(m, 2H), 4.96 (q, T=9.042, 1H), 5.05 (d, T=3.942, 1H),
5.11 (d, T=6.342, 1H), 7.00-7.10 (m, 1H), 7.22-7.40 (m,
2H), 9.36 and 8.97 (m, 1H).

30 mg Submitted as ~~APC~~

AD-C 126532XX



COMPLETED 23/7/98 1ASchaller 13/11/98

READ AND UNDERSTOOD BY

2295

29-7-98

The Attempted Preparation of [1S-(1x, 2x, 3β, 5β (1S*, 2R*))]-3-[5-Butylthio-7-[[2-(3,4-difluorophenyl)cyclopropyl]amino]-3H-[1,2,3]-triazolo[4,5-d]pyrimidin-3-yl]-3-hydroxyethyl-cyclopentane-1,2-diol



 $C_{28}H_{34}F_2N_6O_4S = 588.68$

 $C_{28}H_{36}F_2N_6O_5S = 506.58$

Protected nucleoside	0.226g	0.384mmol	equiv	2295/175/2
80% AcOH/H ₂ O	10ml			
10% K ₂ CO ₃ /H ₂ O	1ml			
MeOH	10ml			

A colourless solution of [3aR-(3aα, 4α, 6α(1R*, 2S*), 6aκ)]-acetic acid, [[6-[5-butylthio-7-[[2-(3,4-difluorophenyl)cyclopropyl]amino]-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl]-tetrahydro-2,2-dimethyl-4H-cyclopenta-1,3-dioxol-4-yl]methyl]ester (0.226g, 0.384mmol) in 80% acetic acid/water (10ml) was heated in an oil bath at 80° for 1 hour. TLC indicated that some reaction had taken place:-

B.T.

2295/175/2
mixed Spot
Reaction mixture
(NaHCO₃/H₂O/EtOH)




SiO₂
5% MeOH/CH₂Cl₂
U.V.

B. Teobald. 12-8-98

179

The reaction mixture was allowed to cool and was cautiously poured into saturated sodium bicarbonate solution (150ml). The resulting emulsion was extracted with ethyl acetate (3x 35ml). The combined organic phases were washed with saturated sodium bicarbonate solution (70ml), dried ($MgSO_4$) and concentrated in-vacuo to give a pale yellow gum (0.220g, 2295/178/1). Tlc indicated that 2295/178/1 was a mixture :-


B.T.



B.T.

2295/178/1 (0.220g) was dissolved in methanol (10ml) and to this ^{pale yellow} ~~colourless~~ solution was added a 10% aqueous solution of potassium carbonate (1ml). The resulting pale yellow solution was stirred at room temperature for 1/2 hour. Tlc indicated that some reaction had taken place :-

B.T.




The reaction mixture was neutralized to pH ~ 7

using a few drops of acetic acid and was then concentrated in-vacuo to give a sticky off-white residue (0.543g, 2295/178/2). Tlc indicated that 2295/178/2 was a mixture:-

B.T.

2295/178/2


 SiO_2 5% MeOH/ CH_2Cl_2

U.V.

2295/178/2 (0.543g) was dissolved in a mixture of dichloromethane and methanol and was adsorbed onto flash silica (5ml, FISHER Matrex 60, 35-70 μ m) in-vacuo. The resulting free-flowing white powder was loaded onto a column of silica (54ml, as above) and eluted with 5% methanol in dichloromethane. Fractions containing essentially pure component 'A' were combined and concentrated in-vacuo to give a colourless residue which was dissolved in diethyl ether and re-concentrated to give a white foam (0.166g, 85%, 2295/178/3). Tlc indicated that 2295/178/3 was pure:-

B.T.

2295/178/3

 SiO_2 5% MeOH/ CH_2Cl_2

U.V.

2295/178/3 (0.166g) was dissolved in a mixture of tetrahydrofuran and acetonitrile

B. Teobald. 12-8-98.

to a concentration of approximately 20 mg/ml. The resulting solution was filtered and aliquots containing ~ 20 mg were purified by preparative HPLC on a Waters Novaapak column eluted with 0.1% aqueous ammonium acetate and acetonitrile, isocratic mixture, 50% acetonitrile over 15 minutes, monitoring at 254 nm.

Fractions containing the main peak were combined and concentrated in-vacuo to remove most of the acetonitrile from the mixture. The resulting sticky suspension was freeze dried to give a white fluffy solid (0.70 g, 2295/178/4).

AN298282 2295/178/4

NMR

^1H D_6 -DMSO Shows the material to be the desired product, essentially pure:-

B.T.

δ_{H} 9.34 & 8.94 (Total 1H, 2x bd, NH); 7.32 (2H, m, H-12 & H-15); 7.06 (1H, m, H-16); 4.99 (2H, m, H-1' & 1x OH); 4.72 (2H, m, 2x OH); 4.43 (1H, m, H-2'); 3.88 (1H, m, H-3'); 3.79 & 3.16 (Total 1H, 2xm, H-8); 3.48 (2H, m, H-6'); 3.10 & 2.93 (Total 2H, 2xm, H-17); 2.26 (1H, m, 1x H-5'); 2.11 (2H, m, H-4' & H-10); 1.84 (1H, m, 1x H-5'); 1.65 & 1.46 (Total 2H, 2xm, H-18); 1.46 (1H, m, 1x H-9); 1.37 (1H, m, 1x H-9); 1.24 (2H, m, H-19), 0.91 & 0.81 (Total 3H, 2xt, 7Hz & 7.3Hz, H-20)


B.T.

B.T.

^{13}C D_6 -DMSO Shows the material to be the desired product, essentially pure:-

δ_c 169.1 (C-5); 153.9 (C-7); 149.4 (dd, 245 Hz & 12 Hz, C-13);
 149.3 (C-3_a); 147.8 (dd, 243 Hz & 13 Hz, C-14);
 139.2 (C-11); 123.2 (C-7_a); 122.8 (C-16);
 117.0 (d, 17 Hz, C-15); 114.8 (d, 18 Hz, C-12);
 74.9 (C-2'); 71.8 (C-3'); 63.0 (C-6'); 62.2 (C-1');
 45.4 (C-4'); 34.0 (C-8); 31.0 (C-17); 30.1 (C-18);
 29.0 (C-5'); 24.0 (C-10); 21.2 (C-19); 15.0 (C-9);
 13.5 (C-20)

B.T.



B.T.

IR. Okay:-

Wave Number (cm-1)	Threshold (%T)
2703	100.2
2361	99.36
2340	99.89
1609	84.73
1589	86.21
1520	85.94
1454	92.2
1430	93.59
1322	81.81
1275	87.42
1211	89.07
1115	89.71
1044	89.71
992	92.51
892	92.97
857	94.53
808	91.41
773	86.68
617	85.54
579	84.26

B. Teobald.

B.T.

HPLC Symmetry C8

0.1% NH₄ OAc (aq) / CH₃CN 25-95% CH₃CN

RT (mins)

%

2.18

99.7

B. Teobald. 12-8-98

183

MS LC/APCI(+ve)

507 (M+H)⁺
507 (100%)

B.T.

m.p. No melting point as material is a freeze dried solid.

B.T.

Elem.

Found

• 1/2 H₂O Requires

⇒ MW = 515.57

%C	H	N	S
53.41	5.47	16.00	6.26
53.58	5.67	16.30	6.22

B.T.

78mg Submitted as AR-C130234XX

B. Teobald. 12-8-98

COMPLETED
READ AND UNDERSTOOD BY


J. C. K. 9-9-98

30-7-98

The Attempted Preparation of [3aR-(3ax,4x,6x,6ax)]-Acetic acid, [[6-[7-amino-5-butylthio-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl]-tetrahydro-2,2-dimethyl-4H-cyclopenta-1,3-dioxol-4-yl]methyl]ester

Ref: 2295/172

B.T.




Protected nucleoside	2.13g	4.88 mmol	2295/164/2
Bromoform	23ml		
ONO	4.7ml		

B.T. A yellow solution of [3aR-(3ax,4x,6x,6ax)]-acetic acid, [[6-[7-amino-5-butylthio-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl]-tetrahydro-2,2-dimethyl-4H-cyclopenta-1,3-dioxol-4-yl]methyl]ester (2.13g, 4.88 mmol) in bromoform (23 ml) and isocyanite (4.7 ml) was heated in an oil bath at 80° for 1/2 hour. TLC of the resulting golden yellow solution indicated that the reaction was complete:-

B.T.

2295/164/2
Mixed Spot
Reaction Mixture




SiO₂
60% Et₂O/isohexane
U.V.

B. Teobald. 12-8-98


2274

148. AR-C126486xx




58%

149.




93%




83%

151.





153.




41%

153.




66%

155.




84%




45%

157. AR-C130237xx




95%




74%

159.




52%



(+8% by product) 65%


161.



75%

30-7-98

~~30-7-98~~ 1S-[1 α ,2 β ,3 β ,4 α (1S*,2R*)]-4-[7-(2-(4-Fluorophenyl)cyclopropylamino)-5-^{butyl}propylthio-3H-1,2,3-triazolo [4,5-d]pyrimidin-3-yl]-cyclopentane-1,2,3-triol.



2274/155 (690mg, 1.34mmol) was dissolved in water (10mL) and TFA (10mL), after stirring for 1 hour reaction was complete by HPLC.

The reaction mixture was added dropwise to sat NaHCO_3 (250mL) soln, and then extracted into ethylacetate (3x100mL).

The organics were dried (MgSO_4), filtered and concentrated to dryness, the residue was then purified by RP-HPLC to give a white solid (620mg, AN 298217).

Yield = 620mg (95%)

AN 298217

Infrared: 1321, 1611, 1588, 1511, 1044, 1228, 818, 789, 1277, 1189, 1028, 834

HPLC: A7505AP.M RT = 2.14min, 99.55%

Mass spec: APCI -ve $\text{M}+\text{H} = 475.1$ (100%)

Elem. anal	C	H	N	S
$\text{C}_{22}\text{H}_{27}\text{FN}_6\text{O}_3\text{S}$	53.99	5.85	17.18	6.54
Found	54.04	5.82	17.02	6.54

AN 298217

proton NMR (300 MHz, d_6 -DMSO)

0.80 t, δ =7.5 Hz, 3H 1)

1.22 sex, δ =7.2 Hz, 2H 2)

1.30-1.35m 1H 7a.)

1.41-1.53m 3H 7b) 3.)

1.86-1.91m 1H 8.)

2.11-2.15m 1H 18a.)

2.51-2.59m 1H 18b.)

2.80-3.00m 2H 4.)

3.13-3.35m 1H 6.)

3.77bs 1H 16.)


3.93bs 1H 15.)

4.63-4.67m 1H 12.)

4.90-4.99m 1H 11.)

7.11 t, δ =9.0 Hz, 2H, 9.)

7.22-7.26m 2H 10.)



melting point: 75-78°C.

590 mg submitted as AR-C130237xx

~~BM~~ 6-8-97